Pharmacology

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

Obscured by the celebratory congratulations and profuse praise of the scientific advance marked by the FDA’s approval of KarXT, now branded Cobenfy, is the revealing and instructive story of how this novel therapeutic agent came to fruition.

Although daptomycin remains more expensive than vancomycin, it is a “suitable alternative” to daptomycin for outpatient parenteral antimicrobial therapy because it results in less health care utilization, researchers reported.

The FDA has recently approved injectable tirzepatide for chronic weight management in adults with overweight or obesity and at least one weight-related condition, such as high BP, type 2 diabetes or higher cholesterol.

The implementation of CancelRx was associated with “an immediate and persistent reduction in the proportion of e-prescriptions” that were sold after they had been discontinued in electronic health records, according to researchers.

Edward Bell, PharmD, BCPS, is a professor emeritus in the College of Pharmacy and Health Sciences at Drake University.

MIAMI BEACH, Fla. — Creation of an interactive online journal club was effective in expanding the body of knowledge for ketamine and related compounds prescribed for psychiatric disorders, according to a presenter.

About half of adults who were prescribed schedule II-controlled stimulants were concurrently exposed to other central nervous system-active drugs, many of which have withdrawal effects, complicating discontinuation, researchers reported.

Twenty-seven brand-name drugs that accounted for nearly $2 billion in Medicare net spending in 2020 received a low added therapeutic benefit rating by health technology assessment agencies in Canada, France and Germany, a recent study found.

Doctoral researchers from 11 European institutions and four companies have formed a research network dedicated to developing molecules that stimulate the immune response to tumor cells.